213 related articles for article (PubMed ID: 29415678)
1. Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells.
Galmarini CM; Martin M; Bouchet BP; Guillen-Navarro MJ; Martínez-Diez M; Martinez-Leal JF; Akhmanova A; Aviles P
BMC Cancer; 2018 Feb; 18(1):164. PubMed ID: 29415678
[TBL] [Abstract][Full Text] [Related]
2. PM060184, a new tubulin binding agent with potent antitumor activity including P-glycoprotein over-expressing tumors.
Martínez-Díez M; Guillén-Navarro MJ; Pera B; Bouchet BP; Martínez-Leal JF; Barasoain I; Cuevas C; Andreu JM; García-Fernández LF; Díaz JF; Avilés P; Galmarini CM
Biochem Pharmacol; 2014 Apr; 88(3):291-302. PubMed ID: 24486569
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of resistance to the microtubule-depolymerizing antitumor compound plocabulin.
Pantazopoulou A; Galmarini CM; Peñalva MA
Sci Rep; 2018 Jun; 8(1):8616. PubMed ID: 29872155
[TBL] [Abstract][Full Text] [Related]
4. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo.
Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W
Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632
[TBL] [Abstract][Full Text] [Related]
5. Deoxypodophyllotoxin exerts both anti-angiogenic and vascular disrupting effects.
Jiang Z; Wu M; Miao J; Duan H; Zhang S; Chen M; Sun L; Wang Y; Zhang X; Zhu X; Zhang L
Int J Biochem Cell Biol; 2013 Aug; 45(8):1710-9. PubMed ID: 23702033
[TBL] [Abstract][Full Text] [Related]
6. Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.
Kretzschmann VK; Gellrich D; Ullrich A; Zahler S; Vollmar AM; Kazmaier U; Fürst R
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):294-303. PubMed ID: 24285578
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of the analogs of plocabulin and their preliminary structure-activity relationship study.
Wang L; Li X; Cui H; Lei X; Liu H; Wang Q; Li Y
Bioorg Med Chem Lett; 2021 Nov; 51():128355. PubMed ID: 34508844
[TBL] [Abstract][Full Text] [Related]
8. Vascular disrupting activity of combretastatin analogues.
Porcù E; Salvador A; Primac I; Mitola S; Ronca R; Ravelli C; Bortolozzi R; Vedaldi D; Romagnoli R; Basso G; Viola G
Vascul Pharmacol; 2016 Aug; 83():78-89. PubMed ID: 27235861
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
[TBL] [Abstract][Full Text] [Related]
10. Effect of the Marine Polyketide Plocabulin on Tumor Progression.
Turrini E; Maffei F; Fimognari C
Mar Drugs; 2022 Dec; 21(1):. PubMed ID: 36662211
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.
Hotchkiss KA; Ashton AW; Mahmood R; Russell RG; Sparano JA; Schwartz EL
Mol Cancer Ther; 2002 Nov; 1(13):1191-200. PubMed ID: 12479700
[TBL] [Abstract][Full Text] [Related]
12. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
13. CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Moon CH; Lee SJ; Lee HY; Dung le TK; Cho WJ; Cha H; Park JW; Min YJ
Invest New Drugs; 2014 Jun; 32(3):400-11. PubMed ID: 24202729
[TBL] [Abstract][Full Text] [Related]
14. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
Ren X; Dai M; Lin LP; Li PK; Ding J
Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
[TBL] [Abstract][Full Text] [Related]
16. Plocabulin Displays Strong Cytotoxic Activity in a Personalized Colon Cancer Patient-Derived 3D Organoid Assay.
Costales-Carrera A; Fernández-Barral A; Bustamante-Madrid P; Guerra L; Cantero R; Barbáchano A; Muñoz A
Mar Drugs; 2019 Nov; 17(11):. PubMed ID: 31752287
[TBL] [Abstract][Full Text] [Related]
17. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A.
Chan A; Singh AJ; Northcote PT; Miller JH
Invest New Drugs; 2015 Jun; 33(3):564-74. PubMed ID: 25822110
[TBL] [Abstract][Full Text] [Related]
19. Vascular disrupting activity and the mechanism of action of EHT 6706, a novel anticancer tubulin polymerization inhibitor.
Belzacq-Casagrande AS; Bachelot F; De Oliveira C; Coutadeur S; Maurier-Mahé F; Throo E; Chauvignac C; Pognante L; Petibon A; Taverne T; Beausoleil E; Leblond B; Pando MP; Désiré L
Invest New Drugs; 2013 Apr; 31(2):304-19. PubMed ID: 22878926
[TBL] [Abstract][Full Text] [Related]
20. CA-1H, a novel oxazole bearing analogue of combretastatin A-4, disrupts the tumor vasculatures and inhibits the tumor growth via inhibiting tubulin polymerization.
Han F; Wang P; Zhang W; Li J; Zhang Q; Qi X; Liu M
Biomed Pharmacother; 2016 May; 80():151-161. PubMed ID: 27133052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
